Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Frequency of Anti-Erythropoietin Antibodies in Patients with End Stage Renal Disease Treated with Recombinant Erythropoietin.

D. Hoppensteadt, PhD, M. Tobu, MD, D. Fareed, BS, O. Iqbal, MD, F. Baltasar, BS, C. Patel, MD, V. Bansal, MD, M. Demir, MD, J. Fareed, PhD

Blood (2005) 106 (11): 3554.

https://doi.org/10.1182/blood.V106.11.3554.3554

Published: 2005

Journal Articles

Molecular Heterogeneity in Recombinant Erythropoietin Using Surface Enhanced Laser Induced Desorption Ionization (SELDI). Clinical Implications.

E. James, BS, J. Maddineni, BS, J. Fareed, PhD, M. Florian-Kujawski, BS, F. Baltasar, BS, W. Jeske, PhD, D. Hoppensteadt, PhD, M. Tobu, MD, M. Demir, MD, O. Iqbal, MD, V. Bansal, MD

Blood (2005) 106 (11): 3557.

https://doi.org/10.1182/blood.V106.11.3557.3557

Published: 2005

Journal Articles

Comparative Study on the Anticoagulant Effects of Low Molecular Weight Heparins as Measured by Whole Blood Act, Anti-Xa and a Newly Developed Prothrombinase Induced Clotting Time (PiCT) Assay.

D. Hoppensteadt, PhD, M. Tobu, MD, R. Wahi, MD, O. Iqbal, MD, J. M. Walenga, PhD, M. Demir, MD, F. Baltasar, BS, J. Fareed, PhD

Blood (2005) 106 (11): 4148.

https://doi.org/10.1182/blood.V106.11.4148.4148

Published: 2005

Journal Articles

Potential Role of ADAMTS13/FXI Complexes in the Pathogenesis of End Stage Renal Disease.

Jawed Fareed, PhD, D. Hoppensteadt, PhD, J. Cunanan, MD, C. Patel, MD, J. Maddineni, BS, F. Baltasar, BS, D. Fareed, BS, M. Demir, MD, M. Tobu, MD, O. Iqbal, MD, V. Bansal, MD, R. Greenfield, PhD

Blood (2005) 106 (11): 4116.

https://doi.org/10.1182/blood.V106.11.4116.4116

Published: 2005

Journal Articles

Clinical and Laboratory Validation of the 2nd International Standard of Low Molecular Weight Heparin (IS 2003-01/608) in the Anti-Xa, Anti-LIA Heptest and Prothrombinase Induced Clotting (PiCT) Tests.

D. Hoppensteadt, PhD, W. Jeske, PhD, D. Fareed, BS, F. Baltasar, BS, J. M. Walenga, PhD, M. Tobu, MD, M. Demir, MD, O. Iqbal, MD, R. Wahi, MD, J. Fareed, PhD

Blood (2005) 106 (11): 4147.

https://doi.org/10.1182/blood.V106.11.4147.4147

Published: 2005

NARROW

Frequency of Anti-Erythropoietin Antibodies in Patients with End Stage Renal Disease Treated with Recombinant Erythropoietin.

Molecular Heterogeneity in Recombinant Erythropoietin Using Surface Enhanced Laser Induced Desorption Ionization (SELDI). Clinical Implications.

Comparative Study on the Anticoagulant Effects of Low Molecular Weight Heparins as Measured by Whole Blood Act, Anti-Xa and a Newly Developed Prothrombinase Induced Clotting Time (PiCT) Assay.

Potential Role of ADAMTS13/FXI Complexes in the Pathogenesis of End Stage Renal Disease.

Clinical and Laboratory Validation of the 2nd International Standard of Low Molecular Weight Heparin (IS 2003-01/608) in the Anti-Xa, Anti-LIA Heptest and Prothrombinase Induced Clotting (PiCT) Tests.

Email alerts

ASH Publications

American Society of Hematology

Frequency of Anti-Erythropoietin Antibodies in Patients with End Stage Renal Disease Treated with Recombinant Erythropoietin.

Molecular Heterogeneity in Recombinant Erythropoietin Using Surface Enhanced Laser Induced Desorption Ionization (SELDI). Clinical Implications.

Comparative Study on the Anticoagulant Effects of Low Molecular Weight Heparins as Measured by Whole Blood Act, Anti-Xa and a Newly Developed Prothrombinase Induced Clotting Time (PiCT) Assay.

Potential Role of ADAMTS13/FXI Complexes in the Pathogenesis of End Stage Renal Disease.

Clinical and Laboratory Validation of the 2nd International Standard of Low Molecular Weight Heparin (IS 2003-01/608) in the Anti-Xa, Anti-LIA Heptest and Prothrombinase Induced Clotting (PiCT) Tests.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only